CARBAMAZEPINE DIHYDRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H12N2O.2H2O
Molecular Weight	272.2991
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.NC(=O)N1C2=CC=CC=C2C=CC3=C1C=CC=C3

InChI

InChIKey=UPTJXAHTRRBMJE-UHFFFAOYSA-N

InChI=1S/C15H12N2O.2H2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17;;/h1-10H,(H2,16,18);2*1H2

HIDE SMILES / InChI

Molecular Formula	C15H12N2O
Molecular Weight	236.2686
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/016608s097,018281s045,018927s038,020234s026lbl.pdf
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/carbamazepine.html http://www.rxlist.com/carnexiv-drug.htm http://www.wikidoc.org/index.php/Carbamazepine

Carbamazepine is an analgesic, anti-epileptic agent that is FDA approved for the treatment of epilepsy, trigeminal neuralgia. It appears to act by reducing polysynaptic responses and blocking the post-tetanic potentiation. It depresses thalamic potential and bulbar and polysynaptic reflexes, including the linguomandibular reflex in cats. Commonly reported side effects of carbamazepine include: dizziness, drowsiness, nausea, ataxia, and vomiting. Carbamazepine is a potent inducer of hepatic CYP1A2, 2B6, 2C9/19, and 3A4 and may reduce plasma concentrations of concomitant medications mainly metabolized by CYP1A2, 2B6, 2C9/19, and 3A4 through induction of their metabolism, like Boceprevir, Cyclophosphamide, Aripiprazole, Tacrolimus, Temsirolimus and others.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Sodium channel protein type 5 subunit alpha 9 Target ID: Q14524\|\|\|E9PFW7 Gene ID: 6331.0 Gene Symbol: SCN5A Target Organism: Homo sapiens (Human) Sources: http://www.drugbank.ca/drugs/DB00564 \| https://www.ncbi.nlm.nih.gov/pubmed/21480866 \| https://www.ncbi.nlm.nih.gov/pubmed/25688050	Blocker 555	152.0 µM [IC50]
Sodium channel protein type 2 subunit alpha 2 Target ID: Q99250 Gene ID: 6326.0 Gene Symbol: SCN2A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20526191 \| https://www.ncbi.nlm.nih.gov/pubmed/20643904 \| https://www.ncbi.nlm.nih.gov/pubmed/12391287	Blocker 555	25.0 µM [Ki]
Sodium channel protein type 3 subunit alpha 2 Target ID: Q9NY46\|\|\|Q9Y6P4 Gene ID: 6328.0 Gene Symbol: SCN3A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17381447	Blocker 555	16.0 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Epilepsy 121 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/016608s097,018281s045,018927s038,020234s026lbl.pdf	Primary		Approved 8583	TEGRETOL Approved Use Epilepsy Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General). Trigeminal Neuralgia Carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. Launch Date 1968
Trigeminal neuralgia 9 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/016608s097,018281s045,018927s038,020234s026lbl.pdf	Primary		Approved 8583	TEGRETOL Approved Use Epilepsy Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General). Trigeminal Neuralgia Carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. Launch Date 1968

C_max

Value	Dose	Analyte	Population
1.9 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CARBAMAZEPINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
0.11 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CARBAMAZEPINE-10,11-EPOXIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
1.5 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARBAMAZEPINE-10,11-EPOXIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
11 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	800 mg 2 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARBAMAZEPINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
4.3 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CARBAMAZEPINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: HIGH-FAT
2.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	800 mg 2 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARBAMAZEPINE-10,11-EPOXIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
3.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	1600 mg 1 times / day multiple, oral dose: 1600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARBAMAZEPINE-10,11-EPOXIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
3.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CARBAMAZEPINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
15.7 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CARBAMAZEPINE-10,11-EPOXIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
32.6 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	1600 mg 1 times / day multiple, oral dose: 1600 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CARBAMAZEPINE-10,11-EPOXIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
37.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CARBAMAZEPINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
34 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CARBAMAZEPINE-10,11-EPOXIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
14.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	800 mg 2 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CARBAMAZEPINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
24% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		CARBAMAZEPINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
50% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		CARBAMAZEPINE-10,11-EPOXIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1000 mg 2 times / day multiple, oral Highest studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17561956	unhealthy, 73.1 ± 5.5 Health Status: unhealthy Age Group: 73.1 ± 5.5 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17561956	Disc. AE: Skin and subcutaneous conditions NEC, Fatigue... AEs leading to discontinuation/dose reduction: Skin and subcutaneous conditions NEC (8.8%) Fatigue Somnolence Sources: https://pubmed.ncbi.nlm.nih.gov/17561956

AEs

AE	Significance	Dose	Population
Skin and subcutaneous conditions NEC	8.8% Disc. AE	1000 mg 2 times / day multiple, oral Highest studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17561956	unhealthy, 73.1 ± 5.5 Health Status: unhealthy Age Group: 73.1 ± 5.5 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17561956
Fatigue	Disc. AE	1000 mg 2 times / day multiple, oral Highest studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17561956	unhealthy, 73.1 ± 5.5 Health Status: unhealthy Age Group: 73.1 ± 5.5 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17561956
Somnolence	Disc. AE	1000 mg 2 times / day multiple, oral Highest studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17561956	unhealthy, 73.1 ± 5.5 Health Status: unhealthy Age Group: 73.1 ± 5.5 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17561956

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inducer 1087			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP2B6 776 UGT2B7 456 UGT1A1 479 UGT1A3 470 UGT1A6 343 UGT1A9 423 UGT2B4 278 UGT1A4 399	CYP1A2 832 CYP2B6 669 UGT1A6 34 UGT1A7 2

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016608s115_018281_s058_018927s055_020234_s047.pdf@page=10 Page: 12.0	strong	yes (co-administration study) Comment: Midazolam plasma concentrations reduced dramatically in patients treated with carbamazepine and phenytoin; The CYP3A4-mediated metabolism of cyclosporin is markedly accelerated by carbamazepine comedication; Many other likely DDIs with carbamazepine. See https://pubmed.ncbi.nlm.nih.gov/8877250/ Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016608s115_018281_s058_018927s055_020234_s047.pdf@page=10 Page: 12.0
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020712s036lbl.pdf#page=12 Page: 12.0	yes
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016608s115_018281_s058_018927s055_020234_s047.pdf@page=10 Page: 10.0	yes
UGT1A6 171	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/29158009/	yes
UGT1A7 25	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/29158009/	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
UGT1A1 479	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15292462/	no
UGT1A3 470	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15292462/	no
UGT1A4 399	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15292462/	no
UGT1A6 343	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15292462/	no
UGT1A9 423	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15292462/	no
UGT2B4 278	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15292462/	no
CYP2B6 776	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/12386121/	yes
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15292462/	yes
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020712s036lbl.pdf#page=12; https://pubmed.ncbi.nlm.nih.gov/8877250/ Page: 12.0	yes	yes (co-administration study) Comment: A 2- to 4-fold increase in serum carbamazepine concentrations has been reported in patients given troleandomycin or erythromycin (CYP3A4 inhibitors); Many other likely DDIs with carbamazepine. See https://pubmed.ncbi.nlm.nih.gov/8877250/ Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020712s036lbl.pdf#page=12; https://pubmed.ncbi.nlm.nih.gov/8877250/ Page: 12.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/17584909/ Page: 6.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3387	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3387
ChemicalBook	CB1143564	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1143564
eMolecules	27677745	https://www.emolecules.com/cgi-bin/more?vid=27677745
eMolecules	535714	https://www.emolecules.com/cgi-bin/more?vid=535714
MolPort	MolPort-000-710-574	https://www.molport.com/shop/molecule-link/MolPort-000-710-574
MolPort	MolPort-023-220-275	https://www.molport.com/shop/molecule-link/MolPort-023-220-275
Selleck Chemicals	Carbamazepine(Carbatrol)	http://www.selleckchem.com/products/Carbamazepine(Carbatrol).html
ZINC	ZINC000000004785	http://zinc15.docking.org/substances/ZINC000000004785

PubMed

Title	Date	PubMed
Changes in color vision after a single dose of vigabatrin or carbamazepine in healthy volunteers.	2001-04-06	11290878
Investigation and medical management of trigeminal neuralgia by consultant oral and maxillofacial surgeons in the British Isles.	2001-04	11286444
Novel treatments for bipolar disorder.	2001-04	11281816
Comparison the cognitive effect of anti-epileptic drugs in seizure-free children with epilepsy before and after drug withdrawal.	2001-04	11255074
Carbamazepine prevents imipramine-induced behavioural sensitization to the dopamine D(2)-like receptor agonist quinpirole.	2001-03-23	11282119
The effects of terpene enhancers on the percutaneous permeation of drugs with different lipophilicities.	2001-03-14	11250108
New anticonvulsants for use in pediatric patients (part I).	2001-03-14	11246198
Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome.	2001-03-07	11231743
Separation of olanzapine, carbamazepine and their main metabolites by capillary electrophoresis with pseudo-stationary phases.	2001-03-05	11254196
Taking the sting out of trigeminal neuralgia.	2001-03	11288566
Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.	2001-03	11284518
Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice.	2001-03	11284448
Treatment of bipolar affective disorder in clinical practice.	2001-03	11277609
Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms.	2001-03	11255328
Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients.	2001-03	11246083
Suppressive effects of oxcarbazepine on tooth pulp-evoked potentials recorded at the trigeminal spinal tract nucleus in cats.	2001-03	11207671
Determination of drug residues in water by the combination of liquid chromatography or capillary electrophoresis with electrospray mass spectrometry.	2001-02-23	11263577
[Febrile convulsions, Treatment and prognosis].	2001-02-19	11242670
[Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of other antiepileptics].	2001-02-17	11234294
A model of atypical absence seizures: EEG, pharmacology, and developmental characterization.	2001-02-13	11171899
Mood stabilizers and ion regulation.	2001-02-13	11159930
Independent short-term variability of spike-like (600 Hz) and postsynaptic (N20) cerebral SEP components.	2001-02-12	11209948
Mood and behavioural disorders following traumatic brain injury: clinical evaluation and pharmacological management.	2001-02	11260764
Determination of the antiepileptics vigabatrin and gabapentin in dosage forms and biological fluids using Hantzsch reaction.	2001-02	11258050
Illness characteristics and their association with prescription patterns for bipolar I disorder.	2001-02	11256463
Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults.	2001-02	11253616
Cardiac arrest after fast intravenous infusion of phenytoin mistaken for fosphenytoin.	2001-02	11240605
Antiepileptic drug withdrawal in patients with temporal lobe epilepsy undergoing presurgical video-EEG monitoring.	2001-02	11240598
Functional changes and adverse reactions after successful treatment of hereditary myokymia: a case report.	2001-02	11239321
Recommendations for the management of behavioral and psychological symptoms of dementia.	2001-02	11237317
Interactions between carbamazepine and polyethylene glycol (PEG) 6000: characterisations of the physical, solid dispersed and eutectic mixtures.	2001-02	11231106
Glutamate receptor antagonists differentially affect the protective activity of conventional antiepileptics against amygdala-kindled seizures in rats.	2001-02	11226813
Prolonged epileptic blindness in an infant associated with cortical dysplasia.	2001-02	11221901
Anticonvulsant and sodium channel blocking activity of higher doses of clenbuterol.	2001-02	11218071
The influence of food on the bioavailability of a twice-daily controlled release carbamazepine formulation.	2001-02	11210399
Relation between dosage of carbamazepine and concentration in hair and plasma samples from a compliant inpatient epileptic population.	2001-02	11206037
Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity.	2001-02	11199933
Pleomorphic xanthoastrocytoma: report of a case diagnosed by intraoperative cytopathological examination.	2001-02	11169891
Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy.	2001-02	11164700
Significance of atypical presentation of symptomatic SUNCT: a case report.	2001-02	11160478
The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained-release morphine in patients pretreated with spinal cord stimulation: a double-blinded randomized study.	2001-02	11159256
[Klüver-Bucy syndrome in herpetic meningoencephalitis].	2001-01-27	11225480
[Carbamazepine-induced SIADH with clinical signs of delirium].	2001-01	11236337
Seizures in multiple sclerosis.	2001-01	11207788
Carbamazepine hypersensitivity syndrome mimicking mycosis fungoides.	2001-01	11204604
Relief of cluster headache and cranial neuralgias. Promising prophylactic and symptomatic treatments.	2001-01	11198259
Ritonavir-induced carbamazepine toxicity.	2001-01	11197575
Acute intermittent porphyria, seizures, and antiepileptic drugs: a report on a 3-year-old Nigerian boy.	2001-01	11181101
New developments in the pharmacotherapy of alcohol dependence.	2001	11268820
Update on anticonvulsants for the treatment of alcohol withdrawal.	2001	11268817

Patents

Sample Use Guides

In Vivo Use Guide

Initial Dose: 400 mg per day. Subsequent Dose: add up to 200 mg per day at weekly intervals. Maximum daily dose is 1600 mg

Route of Administration: Other

In Vitro Use Guide

Human liver microsomes (HLMs) converted carbamazepine (30-300 microM) to 3-hydroxycarbamazepine at rates >25 times those of 2-hydroxycarbamazepine. Rates of carbamazepine 2- and 3-hydroxylation correlated strongly with CYP2B6 activity (r >or= 0.757) in a panel of HLMs (n = 8). Carbamazepine 3-hydroxylation also correlated significantly with CYP2C8 activity at a carbamazepine concentration of 30 microM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:42:46 GMT 2025` Edited by `admin` on `Mon Mar 31 19:42:46 GMT 2025`
Record UNII	78M1RMW7Q8
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CARBAMAZEPINE DIHYDRATE

Common Name

English

5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE, HYDRATE (1:2)

Preferred Name

English

Code System Code Type Description

PUBCHEM

158856

Created by admin on Mon Mar 31 19:42:47 GMT 2025 , Edited by admin on Mon Mar 31 19:42:47 GMT 2025

PRIMARY

CAS

85756-57-6

Created by admin on Mon Mar 31 19:42:47 GMT 2025 , Edited by admin on Mon Mar 31 19:42:47 GMT 2025

PRIMARY

EPA CompTox

DTXSID00235052

Created by admin on Mon Mar 31 19:42:47 GMT 2025 , Edited by admin on Mon Mar 31 19:42:47 GMT 2025

PRIMARY

FDA UNII

78M1RMW7Q8

Created by admin on Mon Mar 31 19:42:47 GMT 2025 , Edited by admin on Mon Mar 31 19:42:47 GMT 2025

PRIMARY

Related Record Type Details


					33CM23913M

Carbamazepine

PARENT -> SALT/SOLVATE


					33CM23913M

Carbamazepine

ANHYDROUS->SOLVATE

Amount:

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound

Drug as perpetrator